bcr1413 BCJ Correction <p>Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]</p> Powles Trevor hdummer@parkside-hospital.co.uk Paterson Alexander McCloskey Eugene Schein Phil Scheffler Bobbi Tidy Alwynne Ashley Sue Smith Ian Ottestad Lars Kanis John

Parkside Oncology, London, UK

Tom Baker Cancer Centre, Calgary, Alberta, Canada

WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

Department of Clinical Pharmacology, University of Oxford, Oxford, UK

Scheffler Group, Villanova, Pennsylvania, USA

Royal Marsden Hospital, London, UK

Radium Institute, Oslo, Norway

 Breast Cancer Research 1465-5411 2006 8 3 406 http://breast-cancer-research.com/content/8/3/406 10.1186/bcr1413 3 5 2006 2006 BioMed Central Ltd

It has been brought to our attention that there was a typographical error in our recent article 1 published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

 <p>Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]</p> Powles T Paterson A McCloskey E Schein P Scheffler B Tidy A Ashley S Smith I Ottestad L Kanis J Breast Cancer Research 2006 8 R13 16542503 10.1186/bcr1384 1557723